MAPT and Alzheimer disease: Gispert et al. [50], investigating CSF CHI3L1 levels between normal, preclinical, and mild dementia, reported that CSF CHI3L1 is associated with a cerebral structural signature distinct from that linked to phosphorylated tau neurodegeneration at the earliest stages of cognitive decline due to AD [49].